uploads///Chart  MRK

How Merck & Co. Stock Performed in 1Q18



A look at Merck & Co.

Headquartered in New Jersey, Merck & Co. (MRK) is one of the oldest and largest pharmaceutical companies by revenue. Merck is doing business as Merck Sharp & Dohme outside the US and Canadian markets.

Merck’s portfolio includes products for both human health and animal health.

The chart above compares Merck & Co.’s revenues and EPS (earnings per share) since 1Q16 as well as estimates for its 1Q18.

Article continues below advertisement

Stock price performance

Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

Analysts’ recommendations

Analysts expect Merck & Co. stock to return ~24.7% over the next 12 months. Analysts’ recommendations show a 12-month target price of $66.55 per share for MRK compared to its price of $53.36 on April 6, 2018.

There are 21 analysts tracking Merck & Co. stock. Six recommend “strong buys,” eight recommend “buys,” and seven recommend “holds” on the stock. The consensus rating for Merck & Co. is 2.05, which represents a moderate buy for long-term growth investors.

Analysts’ revenue estimates

Merck’s revenue is driven by the strong sales of its drugs Gardasil, Keytruda, and Proquad/Varivax in the human health portfolio and a few products in the animal health portfolio.

Wall Street analysts expect Merck & Co.’s revenue to be $10.1 billion in 1Q18, a 6.6% rise compared to 1Q17. They expect its EPS to be $0.99 in 1Q18.

The iShares US Pharmaceuticals ETF (IHE) holds 7.6% of its total investments in Merck & Co., 3.6% in Mylan NV (MYL), 6.5% in Bristol-Myers Squibb (BMY), and 10.6% in Johnson & Johnson (JNJ).

Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!


More From Market Realist